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1. Introduction 
Ishak (modified Knodell score) and METAVIR scores are the most widely accepted scoring 
systems for assessment of fibrosis and necroinflammation in dealing with chronic hepatitis 
C. In METAVIR, only interface hepatitis and lobular necrosis determine the grade of 
activity, while in Ishak, portal infiltrate and confluent necrosis are included with the two 
previous parameters. Confluent necrosis is very rare in chronic hepatitis C, that in most 
patients the actual score limit is 12 instead of 18 (Ishak score), that mostly underscore the 
actual necroinflammation. Also, portal inflammatory infiltrate may reflect immunological 
response rather than necroinflammation. This may explain the discrepancy between enzyme 
elevation and necroinflammatory score as determined by Ishak score (modified HAI) in 
assessment of chronic hepatitis C biopsy specimens. On the other hand, no study has clearly 
tested such discrepancy in applying METAVIR. 
Some of the terminologies applied in METAVIR are in need of revision or declaration. For 
example; the term “septa” is used to mean actual fibrous bridges, while in Ishak score both 
terms; septa and bridges; are applied by different meaning.  Ishak et al, 1995, in their system, 
applied both terminologies (septa & bridges), however in completely different meaning. 
Septa, means expansion of portal tract edges without formation of bridges or actual 
connection between portal areas or portal area and central vein (1). On the other hand, the 
term bridge was applied to actual fibrous connection between two portal areas or portal 
area and central vein. Because of this confusion, some studies comparing both scoring 
systems have committed some mistakes.   
Some studies have compared both Ishak and METAVIR systems, but they included small 
number of patients or included hepatitis B and hepatitis C. Therefore, the objectives of this 
chapter are: 
 Revision of histological grading and staging in chronic hepatitis C. 
 Clarification of the METAVIR terminology for future applications. 
 Establishing an Ishak to METAVIR fibrosis score conversion table. 
2. Histological grading and staging in chronic hepatitis C 
The new approach to classify chronic hepatitis C involves three separate considerations. The 
first is a comment on etiology. Frequently, this cannot be determined on the basis of 
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histological appearance alone, and the diagnosis is made on the basis of other laboratory 
investigations. The second assessment relates to the severity and distribution of 
necroinflammatory activity (histological “grade”). Thirdly, an attempt should be made to 
assess the degree of fibrosis (histological “stage”) (2).   
3. Patterns of necroinflammatory activity 
Inflammatory activity in the liver can be divided into two main components. The first 
involves portal tracts (portal hepatitis) with variable extension into the adjacent periportal 
regions (periportal hepatitis). The second involves liver parenchyma (lobular hepatitis). 
These different patterns of inflammation are probably related to the different pathways 
whereby circulating inflammatory cells can gain access to the liver (3).  
3.1 Portal / periportal hepatitis 
Inflammatory cells migrating across the endothelium of portal vessels pass into portal 
connective tissue which is rich in antigen presenting dendritic cells. A predominantly portal 
inflammatory infiltrate is one of the characteristic histological features of chronic hepatitis. 
However it should kept in mind that portal hepatitis by itself does not necessarily indicate a 
diagnosis of chronic hepatitis. Mild portal inflammatory changes, indistinguishable from 
low-grade chronic viral hepatitis, can be seen in a variety of conditions including systemic 
illness, nearby space-occupying lesion and even in some livers, which otherwise would be 
considered as normal. Furthermore, a predominantly portal inflammatory infiltrate is 
sometimes present in cases of acute viral hepatitis, without any implication of chronicity (4).  
Considerable attention has focused on the extension of portal inflammatory cells into the 
adjacent liver parenchyma associated with destruction of the limiting plate and damage to 
periportal hepatocytes (interface hepatitis) (5).  
3.2 Lobular hepatitis 
Inflammatory cells migrating across the endothelium of hepatic sinusoids can gain direct 
access to the liver parenchyma causing lobular inflammation. Typically this presents as 
“spotty” inflammation dispersed randomly throughout the liver parenchyma. In some cases 
inflammatory changes are more pronounced in perivenular (acinar zone 3) region and are 
associated with areas of confluent necrosis. When areas of zone 3 necrosis link vascular 
structures, in particular portal tracts to hepatic venules, the term “bridging necrosis” is 
used. Rarely in severe cases, there may be complete destruction of hepatocytes in one or 
more acini (panacinar necrosis or multiacinar necrosis) (6). 
3.3 Functional significance of necroinflammatory activity 
The main purpose in identifying different patterns of necroinflammatory activity is that 
these may have different functional and prognostic significance in terms of progression to 
fibrosis and ultimately cirrhosis. 
Interface hepatitis has long been considered as an important lesion in the evolution of 
chronic hepatitis to cirrhosis. In the original classification proposed by De Groote et al, 1968 
(7), chronic persistent hepatitis (portal inflammation without piecemeal necrosis) was 
thought to have a favorable prognosis, whereas chronic active hepatitis (portal inflammation 
with piecemeal necrosis) was regarded as having substantial risk for progression to 
cirrhosis. Interface hepatitis with associated periportal liver cell loss and collapse of the 
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reticulin framework can readily be visualized as a mechanism for the development of 
periportal fibrosis (2).  
There have been few attempts to validate this lesion as a prognostic feature in serial 
biopsies. One study showed that the presence of interface hepatitis in initial biopsies from 
patients with chronic hepatitis correlate with subsequent development of cirrhosis (8). Two 
other studies have demonstrated an association between the severities of necroinflammatory 
activity (including interface hepatitis as a major component) in an initial biopsy and the 
development of fibrosis or cirrhosis in follow up biopsies (9). 
Bursts of lobular inflammatory activity are thought to be particularly important in 
pathogenesis of chronic hepatitis C infection, where progression to cirrhosis is common 
despite the lack of interface activity (10). For these reasons it has been suggested that the 
pattern and severity of lobular inflammation should be taken in account in assessing the 
outcome in cases of chronic hepatitis (11). 
3.4 Assessment of hepatic fibrosis 
In the majority of cases fibrosis begins as expansion of portal tracts occurring in association 
of interface hepatitis. As fibrosis progresses, there is formation of septa with the 
development of portal-portal linkage. Eventually hepatocyte nodules are completely 
surrounded by fibrous tissue. Development of established cirrhosis usually takes several 
years. However, in some situations (e.g. viral hepatitis recurring following liver 
transplantation) cirrhosis can develop much more quickly. Parenchymal fibrosis can also 
occur in presence of lobular inflammation, particularly in areas of bridging necrosis (12). 
This may be responsible of for formation of portal-central septa, which have been regarded 
as more significant in the development of cirrhosis than portal-portal linkages (13).   
4. Historical perspectives: The terminology of chronic hepatitis 
The work of the two decades preceding the Knodell HAI provided the foundation for our 
current understanding of the histopathology of chronic hepatitis. Early descriptions and 
classifications focused on differentiating acute and chronic hepatitis and on lesions that 
predicted disease progression. The first histological classification, which was published by De 
Groote in 1968 (7), codified the terminology, chronic persistent and chronic aggressive 
hepatitis. Both conditions involved portal inflammation, but were distinguished by the 
severity of piecemeal necrosis, inflammation, and structural remodeling of the liver. 
Inflammatory activity was graded as moderate or severe, but exact criteria were not given. The 
classification system also incorporated the concept that chronic persistent hepatitis had a 
generally good prognosis whereas chronic aggressive hepatitis could evolve to cirrhosis (7). 
Popper and Schaffner (1971) (14) affirmed the value of liver biopsy for diagnosis and 
prognosis and recommended use of “topographic” descriptors for hepatitis, that is, chronic 
lobular, chronic portal, or chronic periportal hepatitis. The last of these, synonymous with 
chronic aggressive hepatitis, was believed to progress, whereas chronic portal hepatitis, 
synonymous with chronic persistent hepatitis, was considered a non-progressive process. 
Chronic lobular hepatitis was a term for histological findings similar to those of acute 
hepatitis, but with a clinical duration of more than 3 months. It was thought to be non-
progressive except when seen in combination with chronic periportal hepatitis. 
The explosion of scientific information on viral and non-viral hepatitis in the last decades of 
the 20th century led pathologists to question the conventional nomenclature of chronic 
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persistent and chronic active (aggressive) hepatitis because of a growing understanding that 
etiology may be more significant than morphological classification in predicting the natural 
history of liver disease. This shift in thinking was driven largely by the apparent 
dissociation between the mild histology of non A-non B hepatitis (hepatitis C) and its 
progressive clinical course. It was found that, in many cases, the lesions of this form of viral 
hepatitis fell between those described as chronic persistent and chronic active hepatitis and 
could not be clearly categorized (15). 
The lack of severe piecemeal necrosis and confluent lobular necrosis resulted in the 
diagnosis of chronic persistent hepatitis, implying a benign course. At the same time, the 
lobular component was being recognized as more significant than portal lesions with 
respect to disease progression. Also, confluent necrosis, which when present in severe 
autoimmune hepatitis and hepatitis B confers an ominous prognosis, is uncommon in 
hepatitis C, and yet progression to fibrosis or cirrhosis occurs in all 3 diseases (2). 
5. Scoring systems currently in use 
For a system to be effective in every day diagnostic practice, it must be simple to 
understand, simple to apply, communicate effectively to the treating clinician, and clinically 
relevant (16). The system that is most appropriate for clinical practice may not be the most 
informative for investigative work (17). 
6. Histological grading and staging of chronic hepatitis (1) (Table 1) 
This scheme represents an extension of the original Knodell system, with a number of minor 
modifications. Firstly, a continuous scale is used for scoring each of the features assessed. 
Secondly, necroinflammatory activity and fibrosis are considered as separate categories. 
Thirdly, confluent necrosis is separated from periportal hepatitis and is included as a 
separate category of necroinflammatory activity. The term interface hepatitis was used in 
place of ‘‘piecemeal necrosis,’’ to reflect the growing evidence that apoptosis, not necrosis, 
occurs at the limiting plate. 
The first category (piecemeal necrosis) scores are defined as follows: 0, no piecemeal necrosis; 
1, focal piecemeal necrosis in few portal areas; 2, focal piecemeal necrosis in most portal 
areas; 3, continuous piecemeal necrosis around <50% of tracts or septa; 4, continuous 
piecemeal necrosis around >50% of tracts or septa.  
The second category (Confluent Necrosis) scores are defined as follows: 0, no confluent 
necrosis; 1, focal confluent necrosis; 2, zone 3 necrosis in some areas; 3, zone 3 necrosis in 
most areas; 4, zone 3 necrosis and occasional portal-central (P-C) bridging; 5, zone 3 necrosis 
and multiple (P-C) bridging; 6, panacinar or multiacinar necrosis. 
The third category (focal lytic necrosis, apoptosis, and focal inflammation) scores are defined 
as follows: 0, No focal necrosis; 1, one focus or less per 10x objective; 2, two to four foci per 
10x objective; 3, five to ten foci per 10x objective; 4, more than ten foci per 10x objective.  
The fourth category (portal inflammation) scores are defined as follows: 0, no portal 
inflammation; 1, mild in some or all portal areas; 2, moderate in some or all portal areas; 3, 
moderate to marked, all portal areas; 4, marked in all portal areas. By combining scores for 
each of the four individual necroinflammatory categories, histological grading scores 
ranging from 0-18 can now be achieved. The overall activity scores are defined as follows: 1-
3, minimal; 4-8, mild; 9-12, moderate; 13-18, severe (1). 
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Modified HAI Grading: Necroinflammatory Scores  
Periportal or 
Periseptal Interface 
Hepatitis 
(piecemeal necrosis) 
(A) 
Score 
Confluent 
Necrosis 
(B) 
Score 
Focal (spotty) Lytic 
Necrosis, Apoptosis, 
and Focal 
Inflammation* 
(C) 
Score 
Portal Inflammation 
(D) 
Score 
Absent 0 Absent 0 Absent 0 None 0 
Mild (focal, few 
portal areas) 
1 
Focal confluent 
necrosis 
1 
One focus or less per 
10x objective 
1 
Mild, some or all 
portal areas 
1 
Mild/moderate 
(focal, most portal 
areas) 
2 
Zone 3 necrosis 
in some areas 
2 
Two to four foci per 
10x objective 
2 
Moderate, some or all 
portal areas 
2 
Moderate 
(continuous around 
<50% of tracts or 
septa) 
3 
Zone 3 necrosis 
in most areas 
3 
Five to ten foci per 
10x objective 
3 
Moderate/marked, all 
portal areas 
3 
Severe (continuous 
around >50% of 
tracts or septa) 
4 
Zone 3 necrosis 
+ occasional 
portal-central 
(P-C) bridging 
4 
More than ten foci 
per 10x objective 
4 
Marked, all portal 
areas 
4 
 
Zone 3 necrosis 
+ multiple P-C 
bridging 
5 
  
Panacinar or 
multiacinar 
necrosis 
6 
*Does not include diffuse sinusoidal infiltration by inflammatory cells.  
 
 
Modified Staging: architectural changes, fibrosis and cirrhosis 
Change Score 
No fibrosis  0 
Fibrous expansion of some portal areas, with or without short fibrous septa 1 
Fibrous expansion of most portal areas, with or without short fibrous septa 2 
Fibrous expansion of most portal areas with occasional portal to portal (P-P) bridging 3 
Fibrous expansion of portal areas with marked bridging [portal to portal (P-P) as well as 
portal to central (P-C)] 
4 
Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis) 5 
Cirrhosis, probable or definite 6 
Additional features that should be noted but not scored: bile-duct inflammation and damage; lymphoid 
follicles; steatosis, mild, moderate, or marked; hepatocellular dysplasia, large- or small-cell; adenomatous 
hyperplasia; iron or copper overload; intracellular inclusions (e.g. PAS-positive globules, Mallory bodies); 
and immunohistochemical findings. Information on viral antigens, lymphocyte subsets, or other features, 
when available, should be recorded and may be semi-quantitatively expressed. 
Modified and reprinted (1). 
Table 1. Ishak Modified HAI (1995) (1). 
The fibrosis scores are defined as follows: 0, no fibrosis; 1, fibrous expansion of some portal 
areas, with or without short fibrous septa; 2, fibrous expansion of most portal areas, with or 
without short fibrous septa; 3, fibrous expansion of most portal areas with occasional portal 
to portal bridging; 4, fibrous expansion of most portal areas with marked bridging (portal to 
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portal as well as portal to central); 5, marked bridging with occasional nodules (incomplete 
cirrhosis); 6, cirrhosis, probable or definite (1).   
Difficulties with the Ishak system have been noted. Use of the X10 objective for the 
evaluation of necroinflammatory foci raises concerns of reproducibility, because the size 
of the field may vary among microscopes. In addition, definitions of a “focus” of 
lymphocytic aggregates, apoptotic hepatocytes, or confluent necrosis may vary among 
pathologists (18). 
7. Algorithm for the grading of activity in chronic hepatitis (METAVIR system) 
(Table 2) 
The French METAVIR Cooperative Study Group stated that another possible approach for 
grading the necroinflammatory activity is to consider that periportal and intra-lobular 
necroinflammatory lesions are related to the same pathologic mechanism and that they must 
be globally assessed. A panel decided to define activity according to its potential predictive 
value for the occurrence of liver fibrosis. They chose to include in algorithm only two 
features (piecemeal necrosis and lobular necrosis) (19). 
Portal inflammation was excluded from the algorithm, because this feature is a prerequisite 
for the definition of chronic hepatitis even without activity. Furthermore they observed a 
strong correlation with piecemeal necrosis, making these two features redundant criteria. 
Piecemeal necrosis was chosen as the first decision criterion because of its proven potential 
value in other types of chronic hepatitis. It was then suspected that another feature, lobular 
necrosis, was of major importance in the prediction of liver fibrosis. It is believed that 
aggravation of chronic hepatitis C occurs through a burst of lobular necrosis, a lesion that is 
frequently present in chronic hepatitis C. The two lesions were therefore combined to 
propose a simple algorithm that defined activity.      
In several existing classifications, the degree of piecemeal and lobular necrosis was 
independently assessed and their scores then added, thus giving each of these two lesions 
the same weight in the definition of activity. The METAVIR system included both piecemeal 
necrosis and lobular necrosis in the definition of activity, but with different values. The 
rationale for overweighting the piecemeal necrosis item by comparison with lobular necrosis 
is that piecemeal necrosis is the major discriminating factor used to grade activity, as shown 
by stepwise discriminate analysis.   
The first criterion (piecemeal necrosis) scores are defined as follows: 0, absent; 1, focal 
alteration of the periportal plate in some portal tracts; 2, diffuse alteration of the periportal 
plate in some portal tracts or focal lesion around all portal tracts; 3, diffuse alteration of the 
periportal plate in all portal tracts.  
The second criterion (focal lobular necrosis) scores are defined as follows: 0, less than one 
necroinflammatory foci per lobule; 1, at least one necroinflammatory foci per lobule; 2, 
several necroinflammatory foci per lobule or confluent or bridging necrosis. The overall 
activity scores are defined as follows: 0, No activity; 1, mild; 2, moderate; 3, severe (20).   
The fibrosis scores are defined as follows: F0, no fibrosis; F1, portal fibrosis without septa; 
F2, portal fibrosis with rare septa; F3 numerous septa without cirrhosis; F4, cirrhosis (19). 
The METAVIR system has the advantage of simplicity, reproducibility and application to a 
large number of biopsies (20). This score is composed of a two-letter and two-number 
coding system: A= histological activity and F= fibrosis (Table 2).  
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Algorithm for evaluation of histological activity 
                                                                                              
A=0 
PMN=0                                                   LN=1                  
A=1 
                                                LN=2                                                        
A=2 
PNN=1                                                    LN=0,1                  
A=1 
                                                   LN=2                                                       
A=2 
                                                 LN=0,1                                                    
A=2 
PMN=2                                      LN=2                                                               
 
PMN=3                                                    LN=0,1,2                  
A=3 
 
PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate; 3, severe; LN, lobular necrosis; 0, no or mild;  
1, moderate; 2, severe; A, histological activity; 0, none; 1, mild; 2, moderate; 3, severe. 
 
Fibrosis Scoring 
Score Description 
0 No fibrosis 
1 Stellate enlargement of portal tract but without septa formation 
2 Enlargement of portal tract with rare septa formation 
3 Numerous septa formation 
4 Cirrhosis 
Modified and reprinted (20). 
Table 2. The METAVIR System. 
LN=0 
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8. Problems with histological scoring 
There are a number of problems which apply to all the scoring systems currently in use. 
 Lack of scientific validation: 
A fundamental problem with histological “scoring” is that the numbers which are generated 
do not represent measurement of continuous variable. Instead, they simply represent 
different categories of severity. This contrasts with biochemical measurements, for example, 
serum transaminases, for which a true numerical progression can be more readily justified 
(21).  
 Observer variation:  
There are problems in obtaining reproducible results, even when scoring system is applied 
by experts in the field of liver pathology. In general, better reproducibility has been obtained 
for scoring fibrosis than for scoring inflammatory activity. This is probably due to imprecise 
terminology which is used in individual histological features. Terms such as “occasional”, 
“some”, or “mild’, “moderate and “severe” are used without defining precisely what these 
mean (22).  
 Sampling Variation:  
Much of the knowledge regarding this problem has come from the examination of 
hepatectomy specimens obtained at liver transplantation. Sampling variation exist, both for 
the grade of necroinflammatory activity and for the stage of fibrosis. For example, small 
areas of multiacinar necrosis can often be found in a liver which otherwise show a relatively 
inactive cirrhosis. These areas are typically subcapsular in location but may be also present 
elsewhere. If a needle biopsy is taken from one of these areas, a “falsely high” inflammatory 
score may be obtained. Chronic viral hepatitis may affect the liver uniformly, but 
considerable variation in the severity of fibrosis can be seen when whole liver are available 
for examination (2).   
 Etiological considerations: 
The scoring systems currently in common use incorporate histological features which may 
be seen in all types of chronic hepatitis. However, different types of chronic hepatitis have 
marked differences in natural history and response to therapy. These differences in behavior 
may be reflected by different patterns of histological damage. For example, ballooning, 
rosetting, and giant cell transformation may be regarded as signs of severe damage in cases 
of autoimmune hepatitis, even in the absence of conspicuous inflammatory activity. Direct 
cytopathic damage (e.g. ballooning or fatty change) may be important in the pathogenesis of 
fibrosis in chronic hepatitis C infection (2).  
9. Terminology in METAVIR 
Terminology in METAVIR as regard fibrosis stage assessment is not clear and confusing; 
with narrow range (F0-F4). F3 indicates numerous septa, however, in practical application 
early (developing) cirrhosis is included too, irrespective of being not described in the score 
details. On the other hand, Ishak fibrosis score is wider (0-6), more sensitive, as well clearly 
separate incomplete (developing, early) cirrhosis from established cirrhosis (1,20,23). 
Rozario and Ramakrishna, 2003(24) have built their analysis, tables and comparison on the 
inaccurate idea that F2 of METAVIR (rare septa) is equal to stage 2 of Ishak. However, the 
correct is that, F1 stage of METAVIR is equal to stages 1&2 of Ishak, and F2 of METAVIR is 
equal to stage 3 of Ishak (occasional bridging fibrosis). This resulted in a defect that may 
affect the idea and the conclusion (4). 
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Applying semi-quantitative terminology reflecting grades of necroinflammatory injury as 
recorded by Ishak may underestimate the severity of these changes. In Ishak scoring, 6 
points out of the 18 are related to confluent necrosis, which is a rare event in chronic 
hepatitis C. 
Elzbieta  and Marek, 2005 (25) reported that, the comparison of three histological scoring 
systems used to evaluate chronic hepatitis (Batts and Ludwig, Ishak et al. and METAVIR 
scoring systems) revealed a high coefficient of positive correlation between the respective 
scales. Thus, the systems seem comparable in the estimation of the inflammation grade and 
stage of fibrosis. Table 2 may be advised for converting fibrosis score from Ishak to 
METAVIR. 
Goodman in his review 2007(26), considered Ishak stage 5 (incomplete cirrhosis) to be 
included in METAVIR F4 stage, that is different from the opinion of Bedossa and others of 
METAVIR group. This is a pitfall that may affect the results of some research studies.  
10. Current applications of Ishak and METAVIR scoring systems 
In assessment of regression of fibrosis after autoimmune hepatitis treatment, Abdalla et al, 
2009 have reported higher sensitivity of Ishak compared with METAVIR in detection of 
fibrosis regression (27). They also found statistically higher sensitivity for quantitative 
assessment of fibrosis by analysis of digitalized pictures of sirus red. Czaja and Carpente 
2004, reported a sensitivity of Ishak in assessment of fibrosis regression (28). Esmat et al, 
2007 (applying Ishak fibrosis score) have demonstrated a correlation between fibrosis score 
and hyaluronic acid level (29). Tsochatzis1 et al 2011, in their meta-analysis of diagnostic 
accuracy of elastography for the diagnosis of severity of fibrosis in chronic liver disease, the 
different stages of fibrosis (scoring systems) were converted to comparable stages in 
METAVIR (30). Goodman 2007, suggested application of METAVIR in routine work, and 
Ishak score in clinical trials, because of higher sensitivity in fibrosis assessment (28). 
Lefkowitch 2007 and Guido et al, 2011, suggested application of any of the scoring systems, 
that is not home made, and the clinicians with whom they work prefer (31,32). 
Although liver biopsy has long been regarded as a gold standard procedure, it has obvious 
limitations. It represents an approximation of liver fibrosis for the whole liver and is, 
therefore, not the gold standard for fibrosis assessment. Nevertheless, it is the best 
procedure currently available (33). Germani et al 2010 recommend liver pathologists to 
perform computer-assisted digital analysis of Sirius red-stained histological sections in 
addition to the scoring system established to describe the stage of the liver disease (34). 
11. Conclusions 
Regarding fibrosis: 
 Ishak and METAVIR are nearly identical; however, Ishak is of a wider scale.   
 The term “Septa” in METAVIR is equal to “bridging fibrosis” in Ishak. 
 F3 stage in METAVIR score includes incomplete (developing) cirrhosis. 
Regarding necroinflammatory injury 
 METAVIR is more sensitive to severe activity and more reproducible. However, 
without numerical scoring that let it less effective for monitoring minor changes.      
 Ishak modified HAI has a wider scale. However, 6 points of it (confluent necrosis) are 
nearly out of the chronic hepatitis C scope. This minimizes the actual scoring to 12 
points instead of 18 in practical application.  
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 The proposed table is advised for unidirectional converting fibrosis scores from Ishak to 
METAVIR. 
 METAVIR F3 stage may better be subdivided into F3a: Marked bridging fibrosis and 
F3b: incomplete (early cirrhosis) (developing cirrhosis). 
More work is needed in: 
 Assessing the validity of the current scoring systems in post-liver transplant patients 
with recurrent HCV especially those with a back ground of graft pathologies such as 
rejection and those with associated HBV or cytomegalovirus and HIV infections. 
 Convertibility of the results of these scoring systems and image pattern of contrast 
enhanced ultrasound of the liver. 
 
 
 
 
 
 
 
 
Modified and reprinted (19). 
 
 
Ishak, 1995. 
Fibrosis:  0-6 
0 
1-2 
3 
4-5 
6 
METAVIR Score. 
Fibrosis: F 0-4 
0 
1 
2 
3 
4 
 
Fig. 1. The METAVIR Fibrosis staging system. F0 is normal liver (no fibrosis).  
F1 = portal fibrosis. F2 = few septa. F3 = many septa. F4 = cirrhosis. 
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Fig. 2. Portal tract expansion by fibrosis, Masson trichrom stain. 
 
 
Fig. 3. Bridging fibrosis , Masson trichrom stain. 
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Fig. 4. Multiple portal-portal bridges, , Masson trichrom stain. 
 
 
 
 
 
Fig. 5. Regenerating nodules rimmed by fibrosis, Masson trichrom stain. 
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Fig. 6. Regenerating nodules rimmed by dense fibrosis, Masson trichrom stain. 
 
 
 
 
Fig. 7. Interface hepatitis, H&E stain. 
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Fig. 8. Evident interface hepatitis with apoptosis, H&E stain. 
 
 
Fig. 9. Confluent necrosis, reticulin collapse , sirus red stain. 
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